$186.11
0.26% day before yesterday
NYSE, May 30, 10:12 pm CET
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

AbbVie Stock News

Neutral
PRNewsWire
2 days ago
Chicago-based institutions aim to create greater awareness for cancer advocacy and to support non-profit cancer organizations NORTH CHICAGO, Ill. , May 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced a multi-year partnership with the Chicago Cubs to support people living with cancer through a campaign called "Striking Out Cancer" which starts today when the Chicago Cubs play the Cincinna...
Positive
Seeking Alpha
3 days ago
Money market funds are booming with $7.2 trillion in assets, offering attractive short-term yields, but rising fees and competition could shake things up. I believe we're nearing a turning point: lower rates may push massive capital into dividend stocks, boosting prices and driving down future yields. In the second half of the article, I highlight three high-quality dividend stocks I believe co...
Neutral
Business Wire
4 days ago
NASHVILLE, Tenn.--(BUSINESS WIRE)--Today, Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, announced a strategic alliance with AbbVie. The alliance aims to accelerate the development of innovative therapies for patients with cancer through collaborative scientific engagement and operational synergies t...
Positive
Seeking Alpha
5 days ago
Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 2025 and the average growth rate at 4.75%. 22 Aristocrats appear both undervalued and offer a projected long-term annualized return of at least 10%, based on dividend yield theory and earnings growth.
Neutral
PRNewsWire
5 days ago
-    Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lung cancer (NSCLC), ABBV-706 in high-grade neuroendocrine neoplasms (NENs) and pivekimab sunirine (PVEK) in blastic plasmacytoid dendritic cell neoplasm (BPDCN). NORTH CHICAGO, Ill.
Negative
The Motley Fool
8 days ago
The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- it could easily flare up again.
Neutral
PRNewsWire
10 days ago
NEW YORK , May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
GlobeNewsWire
11 days ago
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Show more news

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today